Biogen Inc (BIIB) Directors and Executive Officers

Officers & Directors

I m sorry, but I can t provide real-time updates or current information about specific individuals, including executives and directors of Biogen Inc. For the most accurate and up-to-date information, please refer to Biogen s official website or recent financial reports.,

Biogen Inc currently has 7500 employees.

News about Biogen Inc Key Personnel

Biogen’s Bold Leap: New Headquarters and Innovations in Neurodegenerative Therapies Set the Stage for a Healthier Future

Biogen Inc. a renowned leader in biopharmaceuticals, is embarking on an ambitious journey that could reshape the landscape of both its operational infrastructure and its contributions to the medical sciences. On March 24, 2025, the company unveiled plans for a new global headquarters and innovation hub situated in the heart of Kendall Square, Cambridge, Massachusetts, marking a pivotal moment in its 50-year history. A New Era in Kendall SquareWith its new headquarters located at 75 Broadway, Biogen aims to consolidate its presence in the vibrant Kendall Square area, a region known for its unparalleled collaboration between science, technology, and education. This consolidation reflects Biogen s commitment to...

Lecanemab's Regulatory Review for Early Alzheimer's Disease Receives Negative Opinion in the European Union

In a recent announcement, Eisai Co., Ltd. and Biogen Inc. revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has rejected the Marketing Authorization Approval (MAA) for lecanemab, a humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody, as a treatment for early Alzheimer s disease (AD). This decision comes as an unfortunate setback in the search for effective therapies to address the devastating cognitive decline associated with AD. Biogen Inc., the key player behind lecanemab, has also experienced a decline in its asset returns. Let s delve into the details.
Lecanemab Faces Regulatory Hurdles:
The CHMP s negativ...

LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China: China Becomes the Third Country to Launch LEQEMBI Following the United States and Japan

In a significant development for Alzheimer s disease patients, the drug LEQEMBI (Lecanemab) has been launched in China. China now becomes the third country after the United States and Japan to introduce this promising treatment for Alzheimer s disease. The launch of LEQEMBI in China is expected to provide new hope for patients and their families in combating this debilitating condition.
Facts:
1. LEQEMBI (Lecanemab) is a drug developed by Biogen Inc, a renowned pharmaceutical company.
2. The drug has shown promising results in clinical trials in the United States and Japan.
3. LEQEMBI is designed to target amyloid-beta plaques, a characteristic feature of Alzheimer s disease.
4....